ReviewFrontiers in cell and developmental biology2026
The role of long non-coding RNAs in therapy resistance of cervical cancer and therapeutic potential.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite significant advances in preventive and early-detection strategies, cervical cancer (CC) continues to pose a substantial clinical burden, especially when confronting the challenge of therapy-resistant or recurrent disease. Long non-coding RNAs (lncRNAs) have emerged as crucial regulators in the development and progression of CC, particularly in mediating resistance to conventional and emerging therapies, including chemotherapy, radiotherapy, and immunotherapy. This review summarizes how specific lncRNAs drive therapeutic resistance through diverse mechanisms such as acting as competitive endogenous RNAs (ceRNAs) to sponge tumor-suppressive microRNAs, and by modulating key signaling pathways like PI3K/Akt and Wnt/β-catenin. Furthermore, we discuss the significant potential of lncRNAs as non-invasive diagnostic and prognostic biomarkers, detectable in liquid biopsies from patient serum or plasma, and as novel therapeutic targets. Advances in targeted strategies have primarily focused on the implementation of precise degradation or interference through antisense oligonucleotides (ASOs) and CRISPR-based systems, highlighting the translational potential of lncRNAs in overcoming refractory therapeutic resistance. Collectively, this review aims to provide a comprehensive overview of the multifaceted roles of lncRNAs in CC therapeutic resistance, offering critical insights that may accelerate the translation of lncRNA-based strategies into clinically actionable interventions to improve patient outcomes in therapy-resistant CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.